Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
about
Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma(1)H NMR Metabolomics Study of Metastatic Melanoma in C57BL/6J Mouse Spleen.Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profilingMetabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain.Delving into somatic variation in sporadic melanoma.Targeting cancer metabolism.Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?Functional effects of GRM1 suppression in human melanoma cells.The association between cancer and amyotrophic lateral sclerosis.Genetics of melanomaThe mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasisU1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In VivoGlutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development.Glutamatergic signaling in cellular transformation.Sorafenib in melanoma.The current management of brain metastasis in melanoma: a focus on riluzole.Metabotropic glutamate receptors in cancer.Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas.Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe (18) F-FITM.Riluzole activates TRPC5 channels independently of PLC activity.Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells.Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic MelanomaA phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.Glutamate Receptor Agonists and Glutamate Transporter Antagonists Regulate Differentiation of Osteoblast Lineage Cells.Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo
P2860
Q30570451-82AA0A4B-B1DD-44C5-A16A-3BFBA7289206Q33769639-3AE94983-2F53-4C09-B177-85D2DBB1CE0BQ34450728-E8F38C95-506B-41DD-96E9-069985214678Q34453064-D5FAC1B0-EC48-4D6E-9F57-05235CB2DE2DQ34525011-4B6ABEF4-1243-4536-8AD9-7A2812292A74Q34737562-F987F93D-CC9A-4B4E-B32F-814235A10864Q34904277-2D0C66E0-21F1-40E8-B0C2-216F06C7E359Q35070083-EC4A0343-9C9F-48FB-AD72-CABE8D430515Q36030770-9D8099A6-C781-44CF-A98B-9BEFF0EF4746Q36330869-A9F8E151-E759-43BA-A1DC-DD2D2A7571E0Q36355920-287A3A74-058F-4620-BB37-DAB145DF3EC6Q36409682-B69ED349-4AD0-4197-9648-F72DA303FC39Q36487523-DCEFA6F9-2BF5-429E-BDAF-9C6582E2340EQ36563659-8BFC3D39-1894-4450-8B49-6C57ECF21EE9Q36582294-07C8FF69-7F82-43DD-A95E-6C5C8A6EA9AEQ36757152-6B537BF5-D9DE-4BE9-AA1E-F05758FA5650Q37121338-BD081FED-A724-4945-8393-30907D11E2F0Q37540105-D31A8128-12C0-4C3B-8C7A-C4DA1A7070B9Q37627169-AE317454-8C2D-4759-8F67-BA043631F25EQ37978409-FCB4170D-624D-433F-861C-9101A5B91BB3Q37990977-B6CE03F1-80A4-45B0-9F18-7FC2E754BD4DQ38532696-D3236C3E-B591-4F58-A12A-D3F76C867A08Q38741884-7958766E-77F1-4EEA-BB2F-CA95C9AAB08EQ38943348-81373C44-22F0-4F60-ADD2-8184F44390A2Q38971337-0184D897-4930-4695-B3AE-983E7AE96D03Q39014061-C7A416F9-D39B-4403-A4A7-684591364760Q39080963-47890B38-87E9-4754-AAA0-89A45F63F5B2Q41280249-4E181F4B-2298-4E5B-B28D-38AD2411F557Q42262009-3B68571D-86F8-495C-81BF-1FBA1034EF0DQ49907440-E1545D91-73EC-43D1-963E-EC79CFA51CACQ53136788-8A6959CE-FC59-4107-B912-9FC9F3964EABQ59137905-30EBA75F-B64E-4074-AA86-FC4B78996CDC
P2860
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
@en
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
@nl
type
label
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
@en
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
@nl
prefLabel
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
@en
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
@nl
P2093
P2860
P1476
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
@en
P2093
Brian A Wall
Hwa Jin Lee
James S Goydos
Janet Wangari-Talbot
Jin Namkoong
Joseph L-K Chan
Seung-Shick Shin
Stephen Rosenberg
Suzie Chen
P2860
P304
P356
10.1158/1078-0432.CCR-11-0098
P407
P577
2011-08-15T00:00:00Z